The February 1, 2011, article by Isakoff et al entitled “Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer” (J Clin Oncol 29:351-354, 2011) was published with errors in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

The COIs were given as:

Employment or Leadership Position: None Consultant or Advisory Role: None Stock Ownership: None Honoraria: None Research Funding: Steven J. Isakoff, Genentech Expert Testimony: None Other Remuneration: None

They should have read as:

Employment or Leadership Position: None Consultant or Advisory Role: **José Baselga, Roche** Stock Ownership: None Honoraria: None Research Funding: Steven J. Isakoff, Genentech Expert Testimony: None Other Remuneration: None

This has been corrected as of January 11, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02189>

The January 20, 2015, article by Weber et al entitled “American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment” (J Clin Oncol 33:278-284, 2015) was published online December 15, 2014, with errors of omission in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Burris’ COIs were given as:

Howard A. Burris III

No relationship to disclose

They should have read as:

Howard A. Burris

Employment: HCA Healthcare/Sarah Cannon

Leadership: HCA Healthcare/Sarah Cannon

Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon

Consulting or Advisory Role: AstraZeneca Pharmaceuticals (Inst), Novartis Pharmaceuticals (Inst), Genentech (Inst), MedImmune (Inst), Astellas Pharma US (Inst), Baxter Healthcare (Inst), Boehringer Ingelheim Pharmaceuticals (Inst), Eli Lilly (Inst), Bayer Healthcare Pharmaceuticals (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Vertex Pharmaceuticals (Inst), Gilead Sciences (Inst), Sanofi-Aventis

U.S. (Inst), Chugai Pharmaceutical (Inst), E.R. Squibb & Sons (Inst), Eisai (Inst), Grifols USA (Inst), Incyte (Inst), Medivation (Inst), Otsuka America Pharmaceutical (Inst), Amgen (Inst), Ipsen Biopharmaceuticals (Inst), Prostrakan (Inst), Tolmar Pharmaceuticals (Inst), Spectrum Pharmaceuticals (Inst), F. Hoffmann-La Roche AG (Inst), Celgene Corporation (Inst)

Research Funding: Genentech (Inst), Bristol-Myers Squibb (Inst), AstraZeneca Pharmaceuticals (Inst), MedImmune (Inst), Novartis Pharmaceuticals (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), Celgene (Inst), Agios (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Immunocore (Inst), Millennium Pharmaceuticals (Inst), BioMed Valley Discoveries (Inst), Pfizer (Inst), TG Therapeutics (Inst), Loxo Oncology (Inst), Vertex Pharmaceutical (Inst), eFFECTOR Therapeutics (Inst), Janssen Research & Development (Inst), Sanofi US Services (Inst), Sanofi-Aventis, Medivation (Inst), Amgen (Inst), Ventana Medical Systems (Inst), Acerta Pharma (Inst), Exelixis (Inst), Array BioPharma (Inst), StemCentrx (Inst), BIND Therapeutics (Inst), Astellas Pharma (Inst), Amplimmune (Inst)

This has been corrected as of January 7, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02274>